NZ510450A - Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis - Google Patents

Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis

Info

Publication number
NZ510450A
NZ510450A NZ510450A NZ51045099A NZ510450A NZ 510450 A NZ510450 A NZ 510450A NZ 510450 A NZ510450 A NZ 510450A NZ 51045099 A NZ51045099 A NZ 51045099A NZ 510450 A NZ510450 A NZ 510450A
Authority
NZ
New Zealand
Prior art keywords
ecrtp
dep
receptor
monoclonal antibody
cells
Prior art date
Application number
NZ510450A
Other languages
English (en)
Inventor
Thomas O Daniel
Takamune Takahashi
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of NZ510450A publication Critical patent/NZ510450A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NZ510450A 1998-09-11 1999-08-31 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis NZ510450A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/152,160 US6248327B1 (en) 1998-09-11 1998-09-11 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
PCT/US1999/019965 WO2000015258A1 (en) 1998-09-11 1999-08-31 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis

Publications (1)

Publication Number Publication Date
NZ510450A true NZ510450A (en) 2003-12-19

Family

ID=22541740

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ510450A NZ510450A (en) 1998-09-11 1999-08-31 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis

Country Status (8)

Country Link
US (1) US6248327B1 (enExample)
EP (1) EP1109578A4 (enExample)
JP (1) JP2002524099A (enExample)
AU (1) AU752649B2 (enExample)
CA (1) CA2343220A1 (enExample)
IL (1) IL141943A0 (enExample)
NZ (1) NZ510450A (enExample)
WO (1) WO2000015258A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176289B1 (en) 1998-09-11 2007-02-13 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
MXPA02008462A (es) * 2000-03-01 2004-05-14 Univ Vanderbilt Modulacion de la actividad de receptor de superficie celular endotelial en la regulacion de angiogenesis.
AUPR598901A0 (en) * 2001-06-28 2001-07-19 Unisearch Limited Inhibition of angiogenesis by targeting protein tyrosine phosphatases
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
EP1490107A4 (en) * 2002-03-21 2005-11-09 Univ Florida MODULATION OF ANGIOGENESIS
AU2003218377A1 (en) * 2002-03-21 2003-10-08 California Institute Of Technology Modulation of angiogenesis through targeting of arginyl transferase (ate1)
US20030194708A1 (en) * 2002-04-10 2003-10-16 Minke Binnerts Human homolog of crossveinless materials and methods
PL377714A1 (pl) * 2002-11-26 2006-02-06 Cold Spring Harbor Laboratory Białka oddziałujące z receptorową tyrozynową fosfatazą białkową DEP-1 oraz sposoby ich wykorzystania
AU2005250341A1 (en) * 2004-04-23 2005-12-15 Amgen Inc. Antibodies to angiogenesis inhibiting domains of CD148
CA2561823A1 (en) * 2004-04-23 2005-12-15 Amgen Inc. Antibodies of angiogenesis inhibiting domains of cd148
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US20090221098A1 (en) * 2006-03-31 2009-09-03 Karima Ferrani-Kile Methods and compositions for obtaining and using biologically active multi-protein complexes
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
US20120183546A1 (en) 2009-09-23 2012-07-19 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
WO2013003606A1 (en) 2011-06-29 2013-01-03 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595911A (en) 1990-03-14 1997-01-21 Cold Spring Harbor Laboratory Isolation of a cDNA encoding a protein tyrosine phosphatase which localizes to focal adhesions
WO1991013989A1 (en) 1990-03-14 1991-09-19 Washington Research Foundation Methods and compositions for the treatment of malignancies in which a protein kinase is associated
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
DE69530261T3 (de) 1994-05-03 2008-07-03 Cold Spring Harbor Laboratory Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen
US5912138A (en) 1996-07-25 1999-06-15 Cold Spring Harbor Laboratory Substrate trapping protein tyrosine phosphatases
AU8479498A (en) 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use

Also Published As

Publication number Publication date
JP2002524099A (ja) 2002-08-06
US6248327B1 (en) 2001-06-19
AU752649B2 (en) 2002-09-26
IL141943A0 (en) 2002-03-10
CA2343220A1 (en) 2000-03-23
AU5797799A (en) 2000-04-03
EP1109578A1 (en) 2001-06-27
WO2000015258A1 (en) 2000-03-23
EP1109578A4 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
US6248327B1 (en) Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
RU2162712C2 (ru) Способы и композиции, пригодные для ингибирования ангиогенеза
JP4763826B2 (ja) Ｖｅｇｆ−関連タンパク質
JP4309383B2 (ja) ヒト化抗ＣＤ１１ａ抗体
US6703018B2 (en) Method of treatment using humanized anti-CD11a antibodies
US20110081292A1 (en) Methods Of Treating Viral Hepatitis
JP2015145397A (ja) 抗α２インテグリン抗体を使用する処置
JP2002524099A5 (enExample)
AU783019B2 (en) Novel method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and beta1 integrins
CN1890567B (zh) 血管发生抑制分子及其在癌症治疗和诊断中的用途
IL151370A (en) An antibody that binds to an epitope with eight amino acids and preparations containing it
US7176289B1 (en) Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
AU2001239898B2 (en) Modulation of the activity of the endothelial cell surface receptor ECRTP/DEP-1 in the regulation of angiogenesis
AU2001239898A1 (en) Modulation of the activity of the endothelial cell surface receptor ECRTP/DEP-1 in the regulation of angiogenesis
MXPA99004795A (en) HUMANIZED ANTI-CD11a ANTIBODIES
HK1097908B (en) Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)